Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

被引:38
|
作者
Salam, Kazi Abdus [1 ]
Akimitsu, Nobuyoshi [1 ]
机构
[1] Univ Tokyo, Radioisotope Ctr, Bunkyo Ku, Tokyo 1130032, Japan
关键词
NONSTRUCTURAL PROTEIN; HELICASE ACTIVITY; PEGINTERFERON ALPHA-2A; ACRIDONE DERIVATIVES; RNA REPLICATION; ION-CHANNEL; P7; PROTEIN; RIBAVIRIN; POTENT; IDENTIFICATION;
D O I
10.1155/2013/467869
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Currently, hepatitis C virus (HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting antivirals (DAAs) against HCV infection are in clinical progress including NS3-4A protease inhibitors, RNA-dependent RNA polymerase inhibitors, and NS5A inhibitors as well as host targeted inhibitors. Two NS3-4A protease inhibitors (telaprevir and boceprevir) have been recently approved for the treatment of hepatitis C in combination with standard of care (pegylated interferon plus ribavirin). The new therapy has significantly improved sustained virologic response (SVR); however, the adverse effects associated with this therapy are still the main concern. In addition to the emergence of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase portion of the HCV NS3 protein. This review article summarizes our current understanding of HCV treatment, particularly with those of NS3 inhibitors.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Mechanisms of hepatitis C virus NS3 proteinase inhibitors
    De Francesco, R
    Pessi, A
    Steinkühler, C
    JOURNAL OF VIRAL HEPATITIS, 1999, 6 : 23 - 30
  • [2] Novel inhibitors of the hepatitis C virus NS3 proteinase
    Bennett, F
    Liu, YT
    Saksena, AK
    Arasappan, A
    Butkiewicz, N
    Dasmahapatra, B
    Pichardo, JS
    Njoroge, FG
    Patel, NM
    Huang, YH
    Yang, XZ
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (19) : 4275 - 4278
  • [3] Hepatitis C virus NS3/4a protease inhibitors
    McCauley, John A.
    Rudd, Michael T.
    CURRENT OPINION IN PHARMACOLOGY, 2016, 30 : 84 - 92
  • [4] Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease
    Zhang, RM
    Durkin, JP
    Windsor, WT
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (07) : 1005 - 1008
  • [5] Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus
    Abian, Olga
    Vega, Sonia
    Sancho, Javier
    Velazquez-Campoy, Adrian
    PLOS ONE, 2013, 8 (07):
  • [6] IDENTIFICATION AND ANALYSIS OF INHIBITORS TARGETING THE HEPATITIS C VIRUS NS3 HELICASE
    Hanson, Alicia M.
    Hernandez, John J.
    Shadrick, William R.
    Frick, David N.
    RNA HELICASES, 2012, 511 : 463 - 483
  • [8] Detection and analysis of hepatitis C virus NS3 serine protease inhibitors
    Zemel, R
    Bachmatove, L
    Berdichevsky, Y
    Kunin, M
    Golan-Goldhirsh, A
    Benhar, I
    Tur-Kaspa, R
    JOURNAL OF HEPATOLOGY, 2001, 34 : 126 - 127
  • [9] The quest for hepatitis C virus NS3 serine protease inhibitors.
    Tur-Kaspa, R
    Berdichevsky, Y
    Zemel, R
    Bachmatov, L
    Lamed, R
    HEPATOLOGY, 2000, 32 (04) : 562A - 562A
  • [10] Molecular docking of peptide inhibitors to the hepatitis C virus NS3 protease
    Shenderovich, M
    Wang, J
    Fisher, C
    Ramnarayan, K
    Abagyan, R
    PEPTIDES FOR THE NEW MILLENNIUM, 2000, : 472 - 473